According to our (Global Info Research) latest study, the global Reritinib Mesylate Tablets market size was valued at US$ 36.01 million in 2025 and is forecast to a readjusted size of US$ 122 million by 2032 with a CAGR of 6.7% during review period.
Reritinib Mesylate Tablets are a highly selective oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with reritinib mesylate as the main ingredient. This drug can irreversibly inhibit EGFR sensitive mutations and T790M resistance mutations, block downstream signaling pathway transmission, inhibit tumor cell proliferation, invasion and metastasis, and exert antitumor effects. Clinically, it is mainly used for locally advanced or metastatic non-small cell lung cancer with EGFR T790M mutation-positive after progression on EGFR tyrosine kinase inhibitor therapy. Characterized by high targeting, convenient oral administration, controllable drug resistance and favorable safety profile, it is an important second-line targeted therapeutic drug for advanced non-small cell lung cancer.In 2025, global Reritinib Mesylate Tablet production reached approximately 120,000 units.
As a domestic third-generation EGFR-TKI, Reritinib Mesylate Tablets are an important innovative product in China's lung cancer targeted therapy market. Relying on its unique molecular structure and excellent clinical efficacy, it has a differentiated advantage in the domestic competitive landscape of third-generation EGFR-TKIs. The drug is approved for non-small cell lung cancer positive for EGFR-sensitive mutations and T790M resistance mutations, with outstanding clinical efficacy and safety. It has also been included in the national medical insurance catalogue, significantly improving patients’ medication accessibility. With the implementation of medical insurance coverage for first-line indications and the upgrading of clinical guideline recommendations, its market penetration continues to rise, forming unique competitiveness among similar domestic drugs. In the future, with the advancement of combination therapy research, indication expansion, and optimization of medical insurance policies, Reritinib Mesylate Tablets will further consolidate its market position, promote a higher level of import substitution of domestic EGFR-targeted drugs, and support the high-quality development of China's precision lung cancer therapy market.
This report is a detailed and comprehensive analysis for global Reritinib Mesylate Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Reritinib Mesylate Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Reritinib Mesylate Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Reritinib Mesylate Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Reritinib Mesylate Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Reritinib Mesylate Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Reritinib Mesylate Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nanjing Sanhome Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Reritinib Mesylate Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100mg / tablet
80mg / tablet
Market segment by Packaging
Bottle
Box
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Production Technology
Innovator
Generic
Market segment by Application
EGFR-Sensitive Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer With T790M Resistance Mutation After Progression on EGFR-TKI Therapy
Second-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer
Others
Major players covered
Nanjing Sanhome Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Reritinib Mesylate Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Reritinib Mesylate Tablets, with price, sales quantity, revenue, and global market share of Reritinib Mesylate Tablets from 2021 to 2026.
Chapter 3, the Reritinib Mesylate Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Reritinib Mesylate Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Reritinib Mesylate Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Reritinib Mesylate Tablets.
Chapter 14 and 15, to describe Reritinib Mesylate Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Reritinib Mesylate Tablets. Industry analysis & Market Report on Reritinib Mesylate Tablets is a syndicated market report, published as Global Reritinib Mesylate Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Reritinib Mesylate Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.